Ahmed Alanazi, Head of Hematology/Oncology Clinical Pharmacy Section at King Fahad Medical City – KFMCK, shared a post on X shared a recent article he and his colleagues co-authored, adding:
“We are pleased to present our findings on the real-world clinical outcomes of Trastuzumab Deruxtecan–Induced Interstitial Lung Disease, as discussed at ESMO25.
These real-world data are pivotal in shaping current clinical practices and in optimizing the efficacy and safety of TDXd, particularly as it advances toward early-stage breast cancer treatment.
Additionally, we would like to share our full data which has been published with the presentation at ESMO25, which is now available in Current Oncology (MDPI).”
Title: Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights from a Tertiary Care Center
Authors: Ahmed S. Alanazi, Ahmed A. Alanazi, Abdalrhman Alanizi, Ranad Babalghaith, Reema Alotaibi, Mohammed Alnuhait, Hatoon Bakhtribah
Read the Full Article on Current Oncology
More posts featuring Ahmed Alanazi.
